Covidien and Nuvo Research FDA action date set for today (NYSE:COV, PINK:NRIFF)

Covidien (NYSE: COV), a leading global provider of healthcare products, and Nuvo Research Inc. (PINK: NRIFF), a Canadian drug development company, both have an action date of today 11/4/2009 from the Food and Drug Administration (FDA) under the Prescription Drug User Fee Act (PDUFA) for their drug Pennsaid (diclofenac sodium) topical solution 1.5%.

Nuvo provided the FDA with supplemental information back in August that caused the FDA to extent its action date by three months to today.

About Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2008 revenue of nearly $10 billion, Covidien has more than 41,000 employees worldwide in 59 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

About Nuvo Research Inc.

Nuvo is focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies. Nuvo’s lead product is Pennsaid, a topical non-steroidal anti-inflammatory drug (NSAID). Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of topical and transdermal products targeting a variety of indications. Nuvo is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany and a research and development Center in San Diego, California. For more information, please visit www.nuvoresearch.com. Pennsaid(R) is a trademark of Nuvo Research, Inc.